0001209191-17-062760.txt : 20171128
0001209191-17-062760.hdr.sgml : 20171128
20171128192657
ACCESSION NUMBER: 0001209191-17-062760
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171125
FILED AS OF DATE: 20171128
DATE AS OF CHANGE: 20171128
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LEE ANN L.
CENTRAL INDEX KEY: 0001723629
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36781
FILM NUMBER: 171226553
MAIL ADDRESS:
STREET 1: 400 DEXTER AVENUE NORTH
STREET 2: SUITE 1200
CITY: SEATTLE
STATE: WA
ZIP: 98109
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Juno Therapeutics, Inc.
CENTRAL INDEX KEY: 0001594864
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 463656275
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 400 DEXTER AVENUE NORTH, SUITE 1200
CITY: SEATTLE
STATE: WA
ZIP: 98109
BUSINESS PHONE: 2065821600
MAIL ADDRESS:
STREET 1: 400 DEXTER AVENUE NORTH, SUITE 1200
CITY: SEATTLE
STATE: WA
ZIP: 98109
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-11-25
0
0001594864
Juno Therapeutics, Inc.
JUNO
0001723629
LEE ANN L.
C/O 400 DEXTER AVENUE NORTH
SUITE 1200
SEATTLE
WA
98109
0
1
0
0
EVP, Technical Operations
Common Stock
2017-11-25
4
A
0
35004
0.00
A
35004
D
Common Stock
2017-11-25
4
A
0
35000
0.00
A
70004
D
Stock Opton (Right to Buy)
62.85
2017-11-25
4
A
0
152900
0.00
A
2027-11-24
Common Stock
152900
152900
D
Represents a restricted stock award ("RSA") granted pursuant to the 2014 Equity Incentive Plan. 50% of the shares subject to the RSA shall vest on each anniversary of November 25, 2017.
Represents a RSA granted pursuant to the 2014 Equity Incentive Plan. The RSA will become eligible to vest based on the achievement of certain performance goals as follows, subject to the reporting person remaining a service provider to the Issuer through the applicable vesting date:
Up to 21,000 shares will become eligible to vest based on the first approval by the U.S. Food & Drug Administration (the "FDA") of JCAR017 in any indication within certain designated timeframes (the "JCAR017 Milestone"). 50% of the shares that become eligible to vest upon the achievement of the JCAR017 Milestone will vest immediately upon such achievement. The remaining 50% of shares that become eligible to vest upon the achievement of the JCAR017 Milestone will vest on the one year anniversary of the date of such achievement.
Up to 9,000 shares will vest based upon the first approval by the FDA of JCARH125 in any indication within certain designated timeframes.
25% of the shares subject to the option shall vest and become exercisable on November 25, 2018 and 1/48th of the shares subject to the option shall vest and become exercisable monthly thereafter.
/s/ Zachary D. Hale, attorney-in-fact
2017-11-28